Classification, diagnosis, and management of orbital venous-lymphatic malformations: Current state-of-the-art.

IF 1 Q4 OPHTHALMOLOGY
Taiwan Journal of Ophthalmology Pub Date : 2025-03-10 eCollection Date: 2025-01-01 DOI:10.4103/tjo.TJO-D-24-00151
Yueh-Ju Tsai, Angel Chao, Yen-Chang Chu, An-Ning Chao
{"title":"Classification, diagnosis, and management of orbital venous-lymphatic malformations: Current state-of-the-art.","authors":"Yueh-Ju Tsai, Angel Chao, Yen-Chang Chu, An-Ning Chao","doi":"10.4103/tjo.TJO-D-24-00151","DOIUrl":null,"url":null,"abstract":"<p><p>Orbital venous-lymphatic malformations (VLMs) are complex vascular anomalies that pose significant challenges to ophthalmologists due to their diverse clinical manifestations and the difficulties inherent in their therapeutic management, particularly given their proximity to critical orbital structures. This narrative review synthesizes the current knowledge on the classification, pathology, molecular mechanisms, imaging characteristics, and therapeutic strategies for VLMs. Historically misclassified as orbital lymphangiomas, VLMs are now recognized as complex malformations comprising interconnected venous and lymphatic components, with the potential for significant complications, including proptosis, visual impairment, and esthetic disturbances. Recent molecular insights have revealed critical pathogenetic mechanisms, particularly mutations in the <i>PIK3CA</i> gene that activate the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin transduction network, alongside the upregulation of vascular endothelial growth factor (VEGF)-mediated signaling. These aberrations not only illuminate the disease etiology but also present promising therapeutic targets. Contemporary management strategies emphasize a multidisciplinary approach, with sclerotherapy emerging as a particularly promising intervention. Sclerosing agents such as bleomycin and pingyangmycin typically yield effective treatment outcomes with relatively favorable safety profiles. Surgical excision is reserved for accessible lesions but often requires adjunctive therapies due to the infiltrative nature of VLMs. Emerging treatments targeting molecular pathways, including PI3K inhibitors and anti-VEGF therapies, show promise in refractory cases. As our understanding deepens, clinicians can now offer more personalized interventions that consider factors such as lesion location, extent, architecture, and hemodynamic characteristics, thereby minimizing morbidity and optimizing clinical and aesthetic outcomes.</p>","PeriodicalId":44978,"journal":{"name":"Taiwan Journal of Ophthalmology","volume":"15 1","pages":"4-13"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Taiwan Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tjo.TJO-D-24-00151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Orbital venous-lymphatic malformations (VLMs) are complex vascular anomalies that pose significant challenges to ophthalmologists due to their diverse clinical manifestations and the difficulties inherent in their therapeutic management, particularly given their proximity to critical orbital structures. This narrative review synthesizes the current knowledge on the classification, pathology, molecular mechanisms, imaging characteristics, and therapeutic strategies for VLMs. Historically misclassified as orbital lymphangiomas, VLMs are now recognized as complex malformations comprising interconnected venous and lymphatic components, with the potential for significant complications, including proptosis, visual impairment, and esthetic disturbances. Recent molecular insights have revealed critical pathogenetic mechanisms, particularly mutations in the PIK3CA gene that activate the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin transduction network, alongside the upregulation of vascular endothelial growth factor (VEGF)-mediated signaling. These aberrations not only illuminate the disease etiology but also present promising therapeutic targets. Contemporary management strategies emphasize a multidisciplinary approach, with sclerotherapy emerging as a particularly promising intervention. Sclerosing agents such as bleomycin and pingyangmycin typically yield effective treatment outcomes with relatively favorable safety profiles. Surgical excision is reserved for accessible lesions but often requires adjunctive therapies due to the infiltrative nature of VLMs. Emerging treatments targeting molecular pathways, including PI3K inhibitors and anti-VEGF therapies, show promise in refractory cases. As our understanding deepens, clinicians can now offer more personalized interventions that consider factors such as lesion location, extent, architecture, and hemodynamic characteristics, thereby minimizing morbidity and optimizing clinical and aesthetic outcomes.

眼眶静脉淋巴畸形的分类、诊断和治疗:最新进展。
眶静脉淋巴畸形(VLMs)是一种复杂的血管异常,由于其多样的临床表现和治疗管理的固有困难,特别是由于其靠近关键的眶结构,给眼科医生带来了巨大的挑战。本文综述了VLMs的分类、病理、分子机制、影像学特征和治疗策略。VLMs过去被错误地归类为眼眶淋巴管瘤,现在被认为是复杂的畸形,包括相互连接的静脉和淋巴成分,具有潜在的严重并发症,包括突出、视力损害和审美障碍。最近的分子研究揭示了关键的发病机制,特别是PIK3CA基因突变激活磷脂酰肌醇3-激酶(PI3K)/AKT/雷帕霉素转导网络的哺乳动物靶点,以及血管内皮生长因子(VEGF)介导的信号传导上调。这些异常不仅阐明了疾病的病因,而且提供了有希望的治疗靶点。当代的管理策略强调多学科的方法,硬化疗法是一种特别有前途的干预措施。硬化剂如博来霉素和平阳霉素通常产生有效的治疗结果,具有相对有利的安全性。手术切除是为可触及的病变保留的,但由于VLMs的浸润性,通常需要辅助治疗。针对分子途径的新兴治疗方法,包括PI3K抑制剂和抗vegf治疗,在难治性病例中显示出希望。随着我们理解的加深,临床医生现在可以提供更多个性化的干预措施,考虑病变位置、范围、结构和血流动力学特征等因素,从而最大限度地降低发病率,优化临床和美学结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
9.10%
发文量
68
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信